Similar articles

• [Physiological trials with MIF-I in Parkinson's disease (author's transl)].

  Gonce M, Barbeau A. Gonce M, et al. Rev Neurol (Paris). 1978 Feb;134(2):141-9. Rev Neurol (Paris). 1978. PMID: 29330 Clinical Trial. French.
• [MIF (melanocyte-stimulating hormone release-inhibiting factor) and Parkinson's disease].

  Carolei A, Meco G, Casacchia M, Agnoli A. Carolei A, et al. Acta Neurol (Napoli). 1976 Jul-Aug;31(4):475-8. Acta Neurol (Napoli). 1976. PMID: 16441 Clinical Trial. Italian. No abstract available.
• [Melanostatin (MIF-1): central action and clinical use].

  Puciłowski O, Płaźnik A, Kostowski W. Puciłowski O, et al. Pol Tyg Lek. 1983 Jun 13;38(24):739-41. Pol Tyg Lek. 1983. PMID: 6139794 Review. Polish. No abstract available.
• Influence of three short-chain peptides (alpha-MSH, MSH/ACTH 4-10, MIF-I on) dimensional attention.

  Beckwith BE, Sandman CA, Kastin A. Beckwith BE, et al. Pharmacol Biochem Behav. 1976;5(Suppl 1):11-6. doi: 10.1016/0091-3057(76)90322-1. Pharmacol Biochem Behav. 1976. PMID: 13409
• CNS and pituitary effects of hypothalamic peptides and MSH.

  Kastin AJ, Miller LH, Sandman CA, Schally AV, Plotnikoff NP. Kastin AJ, et al. Essays Neurochem Neuropharmacol. 1977;1:139-76. Essays Neurochem Neuropharmacol. 1977. PMID: 30623 Review.